![]() Adocia Adocia is a clinical-stage biotechnology company that specializes in the research and development of innovative formulations of already-approved therapeutic proteins. | ![]() Lion TCR Lion TCR is a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases. | ![]() Vericel Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. | |
Founding Date | Founding Date 2005 | Founding Date N/A | Founding Date 1989 |
Type | Type Public | Type Private | Type Public |
Tags | |||
Locations | Locations Lyon-3E-Arrondissement, FR HQ | Locations Singapore, SG HQ Guangzhou, CN Singapore, SG Singapore, SG | Locations Cambridge, US HQ Ann Arbor, US |
Employees | Employees 75 | Employees N/A | Employees 24112% increase |
Valuation ($) | Valuation ($) 158 m | Valuation ($) N/A | Valuation ($) 2.2 b |
Financial | |||
Revenue (est.) | Revenue (est.) €1.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $276.3m (FY, 2025) |
Cost of goods | Cost of goods €792k (FY, 2025) | Cost of goods N/A | Cost of goods $70.7m (FY, 2025) |
Gross profit | Gross profit €3.1m (FY, 2025) | Gross profit N/A | Gross profit $205.6m (FY, 2025) |
Net income | Net income (€16.6m) (FY, 2025) | Net income N/A | Net income $16.5m (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 37m | Total funding raised $ 20m | Total funding raised N/A |

Lion TCR is a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases.
View company
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions.
View company